About US
Contact us
-
Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conferenceThere are big questions facing some of pharma's key players this year, like whether the Pfizer ($PFE) and Allergan ($AGN) deal will get done and why Allergan thinks that is its best route. Or what Myl2016/1/8
-
CEO Frazier expects Merck to be player in hep C market, M&A this yearMerck & Co.'s ($MRK) CEOKenneth Frazierexpects his company to be a player in the lucrative hepatitis C market again with the anticipated approval this month of its hep C candidate. That, along wit2016/1/7
-
Novartis, not to be outdone by respiratory rivals, inks 'smart inhaler' dealRespiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis ($NVS) wants a part of it. TheSwiss drugmaker is collaboratin2016/1/7
-
Takeda snatches Baxalta plant to produce Entyvio in U.S.Takeda Pharmaceutical CEOChristophe Weberis in the midst of crafting the Japanese company's turnaround, and a piece of that effort isEntyvio, a drug he says should chip in $2 billion at its peak. Webe2016/1/6
-
No M&A? No problem, Actelion says as it rolls out $160K-plus UptraviActelion ($ATLN) predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work2016/1/6
-
FDA grants orphan drug status for GBT's once-daily therapy to treat sickle cell diseaseThe US Food and Drug Administration (FDA) has granted orphan drug designation for Global Blood Therapeutics' (GBT) once-daily therapy GBT440 to treat patients with sickle cell disease (SCD), an inheri2016/1/5
-
Lixte licenses lead cancer compound to Taipei Medical University for new HCC treatmentUS-based Lixte Biotechnology Holdings has granted an exclusive licence of its lead anti-cancer compound, LB-100, to Taipei Medical University (TMU). The compound will be used to develop new treatment2016/1/5
-
Sanofi Pasteur's dengue vaccine Dengvaxia gets approval in PhilippinesSanofi Pasteur has received marketing approval from the Philippines' Food and Drug Administration for Dengvaxia to prevent all four dengue types in individuals aged from nine to 45 years and living in2016/1/4
-
Bayer and CRISPR to form JV to develop new treatments for serious genetic diseasesBayer has entered an agreement with CRISPR Therapeutics to establish a joint venture (JV) to develop new breakthrough therapeutics for curing blood disorders, blindness and congenital heart disease.2016/1/4
-
CFDA issues Naming Rules for Medical Device Generic NameChina Food and Drug Administration (CFDA) recently issued the Naming Rules for Medical Device Generic Name, which will be implemented as of April 1, 2016.2015/12/31